Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CRISPRCINIMM

Financiado

Revealing genes that mediate the CIN-induced interferon-inflammatory response us...

Revealing genes that mediate the CIN-induced interferon-inflammatory response using a Genome-wide CRISPR screen coupled to a Suicide Gene Switch. Chromosomal instability (CIN) and the resulting aneuploidies can fuel the dramatic karyotype changes characteristic of tumorigenesis, helping tumors to alter the expression of immune checkpoints and evolving phenotypes related to... ver más

31/12/2024

UNIVERSITAIR MEDIS...

188K€

Presupuesto del proyecto: 188K€

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-22

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

UNIVERSITAIR MEDISCH CENTRUM...

187.62K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTI2018-102204-B-I00 MECANISMOS DE RESISTENCIA A TERAPIAS ANTITUMORALES 375K€ Cerrado

PID2019-111356RA-I00 TERAPIAS DIRIGIDAS CONTRA LA INESTABILIDAD CROMOSOMICA EN CA... 169K€ Cerrado

FJC2019-039523-I Interrogating the cancer genome to find stress-resistance ge... 50K€ Cerrado

HOPE Host Protective Engineering of Cancer Immunity by Targeting... 2M€ Cerrado

RTI2018-102035-B-I00 ESTUDIO DE REORDENAMIENTOS GENETICOS NTRK CON ACTIVIDAD ONCO... 182K€ Cerrado

CancerCirculome Circular DNA driven cancer genome remodeling 1M€ Cerrado

Duración del proyecto: 25 meses Fecha Inicio: 2022-11-22
Fecha Fin: 2024-12-31

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 188K€

Descripción del proyecto Chromosomal instability (CIN) and the resulting aneuploidies can fuel the dramatic karyotype changes characteristic of tumorigenesis, helping tumors to alter the expression of immune checkpoints and evolving phenotypes related to immune evasion or stimulation. Anti-tumor immunity appears to be dependent on the type and origin of the tumor, while immune evasion has become an obstacle to designing effective anticancer therapeutics. Understanding when CIN promotes or suppress anti-tumor immunity is therefore needed. However, the mechanism and initiators by which this adjustment occurs and the role that aneuploidy, CIN or specific karyotypes have in this transition are still in the dark. In order to understand how CIN drives tumor evolution, we need to know how CIN guide cells into different immunogenic responses. Identifying the genes that adjust the role of CIN and aneuploidy in immune evasion can therefore help us unravel the origins of malignant growth and in the future develop more appropriate therapeutic approaches. My project plan is set to find the genes that trigger and connect chromosome missegregation to the interferon-inflammatory response in cells suffering from CIN using an unbiased genome-wide CRISPR KO screen coupled to a suicide gene switch in human fibroblasts. The use of a suicide gene switch, normally used for cell-based therapy, allows separation of cells that have lost the inflammatory pathway while the screen, along with a next generation sequencing, will find the genes related to that loss. This screen will serve as a base to understand what underlies cancer immune evasion in chromosomally unstable cells.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores